Puregon Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Follitropin β

Indications/Uses

Female infertility in anovulation [including polycystic ovarian syndrome (PCOS) in women unresponsive to treatment w/ clomifene citrate] & controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (eg, in vitro fertilization/embryo transfer, gamete intra-fallopian transfer & intracytoplasmic sperm inj). Spermatogenesis deficiency due to hypogonadotrophic hypogonadism in males.

Click to view Puregon detailed prescribing information

Dosage/Direction for Use

Individualized dosage. Female Anovulation Starting dose: 50 IU daily maintained for at least 7 days. If there is no ovarian response, gradually increase daily dose until follicle growth &/or plasma oestradiol levels indicate an adequate pharmacodynamic response. Maintain daily dose until pre-ovulatory conditions are reached. Controlled ovarian hyperstimulation in medically assisted reproduction programs Starting dose: 100-225 IU for at least the 1st 4 days. May individually adjust dosage based upon ovarian response. Can be given either alone or in combination w/ a GnRH agonist or antagonist (for premature luteinisation prevention). Higher total Puregon treatment dose may be required to achieve an adequate follicular response, when using a GnRH agonist. Male 450 IU wkly, preferably in 3 divided doses, given concomitantly w/ hCG. Continue treatment for at least 3-4 mth.

Click to view Puregon detailed prescribing information

Overdosage

View Puregon overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. Ovarian, breast, uterine, testicular, pituitary or hypothalamic tumors. Primary gonadal failure. Females: Undiagnosed vag bleeding. Ovarian cysts or enlarged ovaries, not related to PCOS. Reproductive organ malformations & uterine fibroid tumors incompatible w/ pregnancy. Pregnancy & lactation.

Click to view Puregon detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Puregon detailed prescribing information

Use In Pregnancy & Lactation

Click to view Puregon detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Puregon detailed prescribing information

Storage

View Puregon storage conditions for details to ensure optimal shelf-life.

Description

View Puregon description for details of the chemical structure and excipients (inactive components).

Action

View Puregon mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Trophic Hormones & Related Synthetic Drugs

ATC Classification

G03GA06 - follitropin beta ; Belongs to the class of gonadotropins. Used as ovulation stimulants.

Regulatory Classification

POM

Presentation/Packing

Form

Puregon soln for inj 300 IU/0.36 mL

Packing/Price

1's

Form

Puregon soln for inj 600 IU/0.72 mL

Packing/Price

1's

Form

Puregon soln for inj 900 IU/1.08 mL

Packing/Price

1's

Puregon

follitropin beta

Manufacturer:

Organon